Redeye provides an initial take following the release of Optomed’s Q4 2025 report. Sales were in line with our projections, while EBIT came in below expectations, mainly due to a one-off cost. Overall, we view the report as decent, but expect some pressure on the share today given the weaker-than-expected EBIT and limited awareness of the tough comparables. We will publish a research update shortly; while we do not anticipate any material changes to our fair value range, we may implement some downward revisions to our short-term sales estimates.
LÄS MER
